Genscript seeks $150m Hong Kong float in 4Q
Genscript Biotech Corp is eyeing a $150m listing in Hong Kong, with the company filing an A1 with the city’s stock exchange via sole sponsor Haitong International Capital.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: